- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 12.08. | eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today | 298 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered... ► Artikel lesen | |
| 12.08. | EXOZYMES INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 08.08. | eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST | 288 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 29.07. | eXoZymes achieves 99% purity in lab-scale NCT production | 1 | Investing.com | ||
| 29.07. | eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity | 400 | ACCESS Newswire | Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.NCT project went from concept to... ► Artikel lesen | |
| 22.07. | eXoZymes meldet Durchbruch bei Bioproduktion von NCT | 3 | Investing.com Deutsch | ||
| 22.07. | eXoZymes achieves breakthrough in NCT biomanufacturing process | 2 | Investing.com | ||
| 22.07. | eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months | 440 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial... ► Artikel lesen | |
| 07.07. | Hedge Fund and Insider Trading News: Bill Ackman, Michael Platt, Scott Bessent, Point72 Asset Management, Berkshire Hathaway, Lakehouse Capital, Exozymes Inc (EXOZ), and More | 38 | Insider Monkey | ||
| 26.06. | eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing | 350 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines... ► Artikel lesen | |
| 20.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.05. | eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast | 452 | ACCESS Newswire | MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 13.05. | eXoZymes reports Q1 results | 2 | Seeking Alpha | ||
| 12.05. | eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today | 308 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that... ► Artikel lesen | |
| 12.05. | EXOZYMES INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.05. | eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST | 381 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines,... ► Artikel lesen | |
| 06.05. | eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health | 304 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier... ► Artikel lesen | |
| 25.04. | EXOZYMES INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.04. | eXoZymes Inc.: Bringing clarity and precision to the cell-free space by introducing exozymes | 1 | GlobeNewswire (USA) | ||
| 12.04. | New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presiden | 953 | ACCESS Newswire | New to The Street debuts its inaugural restaurant segment featuring BlackBarn with owner and chef John Doherty NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 / New to The Street, a leading financial... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,550 | -0,25 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
| BIONTECH | 83,50 | -0,77 % | Laufende Fusionskontrollverfahren: BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., Tübingen | Datum der Anmeldung:18.09.2025Aktenzeichen:B3-86/25Unternehmen:BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., TübingenProduktmärkte:biotechnologische... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,625 | -0,22 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
| EVOTEC | 5,940 | -1,62 % | Puma Aktie: Neue Gerüchte - Aumovio, Circus, Evotec, Krones und Novo Nordisk im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 7,040 | +106,45 % | Bioaffinity Technologies stock soars after lung cancer test aids early detection | ||
| VALNEVA | 4,274 | -1,02 % | Valneva: Aktie steigt weiter - Warnung vom Auswärtigen Amt | Die Aktie von Valneva setzt auch am heutigen Freitag ihre kräftige Aufholjagd fort. Ein Großteil des Kurseinbruchs von Mitte August ist damit mittlerweile bereits ausgebügelt. Beflügelt wird die Aktie... ► Artikel lesen | |
| JANUX THERAPEUTICS | 21,900 | +0,69 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| NUVALENT | 77,53 | 0,00 % | Nuvalent schließt FDA-Zulassungsantrag für Lungenkrebsmedikament Zidesamtinib ab | ||
| PEPGEN | 4,860 | -16,57 % | Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings | OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,820 | -1,17 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| CG ONCOLOGY | 37,040 | +1,51 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| BB BIOTECH | 37,950 | -1,17 % | EQS-News: BB BIOTECH AG: BB Biotech wird in den SPI ESG Index aufgenommen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): ESG
BB Biotech wird in den SPI ESG Index aufgenommen
22.09.2025 / 07:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| TOURMALINE BIO | 47,760 | +0,06 % | Tourmaline Bio To Be Acquired By Novartis; Was TRML Stock In Your Investment Portfolio? | BASEL (dpa-AFX) - Tourmaline Bio Inc. (TRML), a late-stage clinical biotechnology company developing medicines for life-altering inflammatory and immune diseases, is all set to be acquired by... ► Artikel lesen | |
| MODERNA | 20,650 | -2,23 % | Moderna-Aktie: Kurs heute im Minus (21,2677 €) | Am US-amerikanischen Aktienmarkt liegt die Aktie von Moderna zur Stunde im Minus. Der jüngste Kurs betrug 24,79 US-Dollar. Eine Verbilligung in Höhe von 1,09 US-Dollar müssen derzeit die Aktionäre von... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,600 | -3,69 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen |
EXOZYMES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 14,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.